E. H. AHRENS JR., M.D.
This content is PDF only. Please click on the PDF icon to access.
To the Editor: It is heartening to note the cautious response of the medical community to recent claims for clofibrate (Atromid-S®) in prevention and treatment of ischemic heart disease. An attitude of caution is entirely appropriate toward any drug affecting so fundamental a process as cholesterol metabolism, particularly with the recent experience with triparanol fresh in mind.
Our research group at The Rockefeller University Hospital is highly interested in this drug, after 4 years' experience with it in closely controlled studies in about 70 patients. Some optimism about its safety is based on the much longer and wider experience of
AHRENS EH. PATIENTS NEEDED FOR CLOFIBRATE STUDIES AT ROCKEFELLER. Ann Intern Med. ;69:637. doi: 10.7326/0003-4819-69-3-637_1
Download citation file:
Published: Ann Intern Med. 1968;69(3):637.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use